<DOC>
	<DOCNO>NCT01792635</DOCNO>
	<brief_summary>This study design assess safety , tolerability pharmacodynamics 6 week oral dos PF-05175157 provide monotherapy subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Subjects diagnose type 2 diabetes mellitus medical professional accord American Diabetes Association guideline . Hemoglobin A1c ≥7 ≤10.0 % subject metforminnaive take metformin 2 month Hemoglobin A1c ≥6.5 ≤9.5 % subject metforminnaïve take SU DPPIVi wash take metformin willing discontinue metformin 8week washout period . Evidence history clinically significant hematological , renal , endocrine ( T2DM hypothyroidism ) , gastrointestinal , cardiovascular , pulmonary , hepatic , psychiatric neurologic disease . A waist circumference make fit imto bore MR scanner impossible . Subjects history dry eye , know ocular systemic disease affect sclera cornea .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Safety &amp; Tolerability</keyword>
</DOC>